Nanotechnology has been referred to as potentially being the next technical revolution that could change the modern world. A large portion of the diverse realm of nanotechnology is the manipulation of matter on the atomic scale, with at least one dimension sized from 1 to 100 nanometers (nm).
Companies manufacturing parenteral drugs and ophthalmic solutions need to test for subvisible particulates using a liquid particle counter. Parenteral drugs must be tested according to USP <788> or <787> for therapeutic proteins. The globule size of lipid injectable emulsions is tested per USP <729> for both the mean size and the percent > 5µm (PFAT5). Ophthalmic solutions are tested following USP <789>.
The cell and gene therapy (C>) fields of biomedical research have similar goals targeting DNA or RNA inside or outside the body by modifying genetic material to improve functioning or to fight disease. Cell therapy introduces new cells into a patient’s body to grow, replace, or repair damaged tissue to treat a disease.
Entegris has applied our uncompromising commitment to quality and purity to helping customers in bioprocess manufacturing. The addition of a single-use, sterilizing grade, PES filter into our life sciences portfolio perfectly complements our existing single-use bioprocess assemblies.
Entegris is playing a supporting but crucial role in our customers’ efforts to develop and manufacture therapies for COVID-19. We have taken several critical steps to bolster supply chains, auditing, and validation programs, and are undergoing rapid scale-up to meet commercial demand for potential successful candidates in the pipeline.